Back to Search
Start Over
The potential of cystatin C as a predictive biomarker in breast cancer.
- Source :
- Expert Review of Anticancer Therapy; Dec2020, Vol. 20 Issue 12, p1049-1056, 8p
- Publication Year :
- 2020
-
Abstract
- Breast cancer (BCa) is the leading cause of cancer-related deaths among women. Numerous efforts are being directed toward identifying novel tissue and/or circulating molecular markers that may help clinicians in detecting early-stage BCa patients and in providing an accurate estimation of the prognosis and prediction of response to clinical treatments. In this setting, emerging evidence has indicated Cystatin C (Cyst C), as the most potent endogenous inhibitor of cysteine cathepsins, as a possible useful marker in the clinical management of BCa patients. This review analyzes the results of emerging studies underpinning a potential clinical role of Cyst C, as additional marker in BCa. Cyst C expression levels have been reported to be altered in tumor tissues and/or in biological fluids of BCa patients. Furthermore, clinical evidence has highlighted a significant correlation between altered Cyst C levels in tumor tissues and/or biological fluids and some clinco-biological parameters of BCa progression. These findings provide evidence for a potential clinical use of Cyst C as a novel marker to improve the clinical and therapeutic management of BCa patients and as a gauge for better clarifying the role of cysteine proteinases in the various steps of BCa progression. [ABSTRACT FROM AUTHOR]
- Subjects :
- CYSTEINE proteinases
BIOMARKERS
BREAST cancer
CATHEPSINS
TUMOR markers
Subjects
Details
- Language :
- English
- ISSN :
- 14737140
- Volume :
- 20
- Issue :
- 12
- Database :
- Complementary Index
- Journal :
- Expert Review of Anticancer Therapy
- Publication Type :
- Academic Journal
- Accession number :
- 147548878
- Full Text :
- https://doi.org/10.1080/14737140.2020.1829481